Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphomas and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.
Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial are among the highlights. Results from the E1910 trial led to an FDA approval in June 2024 after it found that adding the immunotherapy drug blinatumomab to standard front-line consolidation chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival.
Details for the presentations are below, listed by type and date. Times are shown in Pacific Time.
PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
Presenter: Ruifeng Sun, BS (Yale University)
Oral Abstract 632 in Session 614
Date and Time: Sunday, December 8, 4:30 - 6:00 PM
Presentation Time: 4:45 PM
Location: Marriott Marquis San Diego Marina, Grand Ballrooms 5-6
Presenters are available for media interviews under the ASH Meeting Embargo Policy. To schedule an interview, send an email to Diane Dragaud, Director of Communications, at communications@ecog-acrin.org.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate cutting-edge genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 cancer centers and community hospitals collaborate across ECOG-ACRIN’s nearly 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health, through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). To learn more, visit www.ecog-acrin.org and follow us on X/Twitter @EAonc, Facebook, LinkedIn, YouTube, and Instagram.
About PrECOG
PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of ECOG-ACRIN. To learn more, visit www.precogllc.org and follow us on X/Twitter @PrECOGonc, Facebook, and LinkedIn.